Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sorafenib in Patients With Hepatopulmonary Syndrome: A Double-Blind Randomized Clinical Trial

Trial Profile

Sorafenib in Patients With Hepatopulmonary Syndrome: A Double-Blind Randomized Clinical Trial

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver disorders; Lung disorders
  • Focus Therapeutic Use
  • Acronyms SHPS
  • Most Recent Events

    • 28 Feb 2019 Primary endpoint (Difference in changes in alveolar-arterial oxygen gradient between sorafenib and placebo groups) has not been met published in the Liver transplantation
    • 28 Feb 2019 Results assessing effect of sorafenib in patients with hepatopulmonary syndrome on the alveolar-arterial oxygen gradient published in the Liver Transplantation
    • 14 Mar 2018 Status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top